Sage Therapeutics is advancing its experimental pill SAGE-217 into a pivotal clinical trial for people with treatment-resistant depression, the company said Wednesday.
Treatment-resistant depression will be the third proposed indication for SAGE-217, a once-daily oral medicine that has already established efficacy in postpartum depression and is being investigated in an ongoing Phase 3 study of major depressive disorder. The Cambridge, Mass.-based company intends to start a Phase 3 study in treatment-resistant depression before the end of the year, said CEO Jeff Jonas said in an interview.
“I have a vision for SAGE-217, which as we place it into the clinical marketplace, we really want it to be first-line every time. To do that, we need to have treatment-resistant depression,” he said.